CD200/BTLA deletions in pediatric precursor B-cell acute lymphoblastic leukemia treated according to the EORTC-CLG 58951 protocol

Haematologica

Volumn 100, Issue 10, 2015, Pages 1311-1319

  Ghazavi, Farzaneh ^a   Clappier, Emmanuelle ^b,c   Lammens, Tim ^a   Suciu, Stefan ^d   Caye, Aurélie ^b,c   Zegrari, Samira ^b   Bakkus, Marleen ^e   Grarde, Nathalie ^f   Benoit, Yves ^a   Bertrand, Yves ^g   Minckes, Odile ^h   Costa, Vitor ⁱ   Ferster, Alina ^j   Mazingue, Françoise ^k   Plat, Geneviève ^l   Plouvier, Emmanuel ^m   Poirée, Marilyne ⁿ   Uyttebroeck, Anne ^o   van der Werff Ten Bosch, Jutte ^e   Yakouben, Karima ^b   Helsmoortel, Hetty ^a   Meul, Magali ^a   Van Roy, Nadine ^a   Philippé, Jan ^p   Speleman, Frank ^a   Cavé, Hélène ^b,c   Van Vlierberghe, Pieter ^a   De Moerloose, Barbara ^a   more..

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

^b HÔPITAL ROBERT DEBRÉ   (France)

^c UNIVERSITÉ PARIS DIDEROT   (France)

^d EORTC DATA CENTER   (Belgium)

^e UNIVERSITY HOSPITAL BRUSSELS   (Belgium)

^f JEAN PIERRE AUBERT RESEARCH CENTER   (France)

^g HOSPICES CIVILS DE LYON   (France)

^h CAEN UNIVERSITY HOSPITAL   (France)

ⁱ PORTUGUESE ONCOLOGY INSTITUTE   (Portugal)

^j HOP UNIV DES ENFANTS REINE FABIOLA   (Belgium)

^k CHR   (France)

^l HÔPITAL DES ENFANTS   (France)

^m UNIVERSITY HOSPITAL OF BESANÇON   (France)

ⁿ CENTRE HOSPITALIER UNIVERSITAIRE DE NICE   (France)

^o UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^p GHENT UNIVERSITY   (Belgium)

more..

Author keywords

[No Author keywords available]

Indexed keywords

B AND T LYMPHOCYTE ATTENUATOR PROTEIN; CD200 ANTIGEN; NUCLEIC ACID BINDING PROTEIN; PROTEIN; UNCLASSIFIED DRUG; ANTIGENS, CD200; ANTINEOPLASTIC AGENT; BTLA PROTEIN, HUMAN; IMMUNOGLOBULIN RECEPTOR; LEUKOCYTE ANTIGEN;

ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; B CELL LEUKEMIA; BLOOD ANALYSIS; CHILD; CHROMOSOME 3; CLINICAL TRIAL; COMPARATIVE GENOMIC HYBRIDIZATION; CONTROLLED STUDY; EVENT FREE SURVIVAL; FEMALE; GENE DELETION; GENE DOSAGE; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC RISK; HUMAN; HUMAN CELL; INFANT; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; POLYMERASE CHAIN REACTION; PROGNOSIS; PROTEIN EXPRESSION; ADOLESCENT; ALLELE; CHROMOSOME BREAKAGE; CLINICAL TRIAL (TOPIC); COPY NUMBER VARIATION; GENE FREQUENCY; GENETICS; KAPLAN MEIER METHOD; MORTALITY; NEWBORN; PRECURSOR B-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PRESCHOOL CHILD; RECURRENT DISEASE;

ADOLESCENT; ALLELES; ANTIGENS, CD; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; CHILD, PRESCHOOL; CHROMOSOME BREAKPOINTS; CLINICAL TRIALS AS TOPIC; COMPARATIVE GENOMIC HYBRIDIZATION; DNA COPY NUMBER VARIATIONS; FEMALE; GENE DELETION; GENE FREQUENCY; HUMANS; INFANT; INFANT, NEWBORN; KAPLAN-MEIER ESTIMATE; MALE; PRECURSOR B-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROGNOSIS; RECEPTORS, IMMUNOLOGIC; RECURRENCE;

EID: 84939133923     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2015.126953     Document Type: Article

References (32)

1. Armstrong SA, Look AT. Molecular genetics of acute lymphoblastic leukemia. J Clin Oncol. 2005;23(26):6306-6315.
2. Mullighan CG, Su X, Zhang J, et al. Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia. N Engl J Med. 2009; 360(5):470-480.
3. Clappier E, Auclerc M-F, Rapion J, et al. An intragenic ERG deletion is a marker of an oncogenic subtype of B-cell precursor acute lymphoblastic leukemia with a favorable outcome despite frequent IKZF1 deletions. Leukemia. 2014;28(1):70-77.
4. Dastugue N, Suciu S, Plat G, et al. Hyperdiploidy with 58-66 chromosomes in childhood B-acute lymphoblastic leukemia is highly curable: 58951 CLG-EORTC results. Blood. 2013;121(13):2415-2423.
5. Domenech C, Suciu S, De Moerloose B, et al. Dexamethasone (6 mg/m2/day) and prednisolone (60 mg/m2/day) were equally effective as induction therapy for childhood acute lymphoblastic leukemia in the EORTC CLG 58951 randomized trial. Haematologica. 2014;99(7):1220-1227.
6. Moricke A, Reiter A, Zimmermann M, et al. Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival: treatment results of 2169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95. Blood. 2008;111(9):4477-4489.
7. Pui C-H, Robison LL, Look AT. Acute lymphoblastic leukaemia. Lancet. 2008;371 (9617):1030-1043.
8. Mullighan CG. Genomic characterization of childhood acute lymphoblastic leukemia. Semin Hematol. 2013;50(4):314-324.
9. Mullighan CG, Downing JR. Global genomic characterization of acute lymphoblastic leukemia. Semin Hematol. 2009;46(1):3-15.
10. Mullighan CG, Goorha S, Radtke I, et al. Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia. Nature. 2007;446(7137):758-764.
11. Dorge P, Meissner B, Zimmermann M, et al. IKZF1 deletion is an independent predictor of outcome in pediatric acute lymphoblastic leukemia treated according to the ALL-BFM 2000 protocol. Haematologica. 2013;98(3): 428-432.
12. Mullighan CG, Miller CB, Radtke I, et al. BCR-ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros. Nature. 2008;453(7191):110-114.
13. Zaliova M, Zimmermannova O, Doerge P, et al. ERG deletion is associated with CD2 and attenuates the negative impact of IKZF1 deletion in childhood acute lymphoblastic leukemia. Leukemia. 2014;28(1):182-185.
14. Bateman CM, Colman SM, Chaplin T, et al. Acquisition of genome-wide copy number alterations in monozygotic twins with acute lymphoblastic leukemia. Blood. 2010;115 (17):3553-3558.
15. Kearney L, Gonzalez De Castro D, Yeung J, et al. Specific JAK2 mutation (JAK2R683) and multiple gene deletions in Down syndrome acute lymphoblastic leukemia. Blood. 2009;113(3):646-648.
16. Kuiper RP, Waanders E, van der Velden VHJ, et al. IKZF1 deletions predict relapse in uniformly treated pediatric precursor B-ALL. Leukemia. 2010;24(7):1258-1264.
17. Lilljebjörn H, Soneson C, Andersson A, et al. The correlation pattern of acquired copy number changes in 164 ETV6/RUNX1-positive childhood acute lymphoblastic leukemias. Hum Mol Genet. 2010;19(16): 3150-3158.
18. Trageser D, Iacobucci I, Nahar R, et al. Pre-B cell receptor-mediated cell cycle arrest in Philadelphia chromosome-positive acute lymphoblastic leukemia requires IKAROS function. J Exp Med. 2009;206(8):1739-1753.
19. De Moerloose B, Suciu S, Bertrand Y, et al. Improved outcome with pulses of vincristine and corticosteroids in continuation therapy of children with average risk acute lymphoblastic leukemia (ALL) and lymphoblastic non-Hodgkin lymphoma (NHL): report of the EORTC randomized phase 3 trial 58951. Blood. 2010;116(1):36-44.
20. Menten B, Pattyn F, De Preter K, et al. ArrayCGHbase: an analysis platform for comparative genomic hybridization microarrays. BMC Bioinformatics. 2005; 6(1):124.
21. Mullighan CG, Downing JR. Genome-wide profiling of genetic alterations in acute lymphoblastic leukemia: recent insights and future directions. Leukemia. 2009;23(7): 1209-1218.
22. Iacobucci I, Storlazzi CT, Cilloni D, et al. Identification and molecular characterization of recurrent genomic deletions on 7p12 in the IKZF1 gene in a large cohort of BCRABL1- positive acute lymphoblastic leukemia patients: on behalf of Gruppo Italiano Malattie Ematologiche dell'Adulto Acute Leukemia Working Party (GIMEMA AL WP). Blood. 2009;114(10):2159-2167.
23. Kuiper RP, Schoenmakers EFPM, van Reijmersdal SV, et al. High-resolution genomic profiling of childhood ALL reveals novel recurrent genetic lesions affecting pathways involved in lymphocyte differentiation and cell cycle progression. Leukemia. 2007;21(6):1258-1266.
24. Ofverholm I, Tran AN, Heyman M, et al. Impact of IKZF1 deletions and PAX5 amplifications in pediatric B-cell precursor ALL treated according to NOPHO protocols. Leukemia. 2013;27(9):1936-1939.
25. Waanders E, van der Velden VHJ, van der Schoot CE, et al. Integrated use of minimal residual disease classification and IKZF1 alteration status accurately predicts 79% of relapses in pediatric acute lymphoblastic leukemia. Leukemia. 2011;25(2):254-258.
26. Vendel AC, Calemine-Fenaux J, Izrael-Tomasevic A, Chauhan V, Arnott D, Eaton DL. B and T lymphocyte attenuator regulates B cell receptor signaling by targeting Syk and BLNK. J Immunol. 2009;182(3): 1509-1517.
27. Zhang SL, Cherwinski H, Sedgwick JD, Phillips JH. Molecular mechanisms of CD200 inhibition of mast cell activation. J Immunol. 2004;173(11):6786-6793.
28. Alapat D, Coviello-Malle J, Owens R, et al. Diagnostic usefulness and prognostic impact of CD200 expression in lymphoid malignancies and plasma cell myeloma. Am J Clin Pathol. 2012;137(1):93-100.
29. Ushmorov A, Leithäuser F, Sakk O, et al. Epigenetic processes play a major role in Bcell- specific gene silencing in classical Hodgkin lymphoma. Blood. 2006;107(6): 2493-2500.
30. Papaemmanuil E, Rapado I, Li Y, et al. RAGmediated recombination is the predominant driver of oncogenic rearrangement in ETV6- RUNX1 acute lymphoblastic leukemia. Nat Genet. 2014;46(2):116-125.
31. Kuster L, Grausenburger R, Fuka G, et al. ETV6/RUNX1-positive relapses evolve from an ancestral clone and frequently acquire deletions of genes implicated in glucocorticoid signaling. Blood. 2011;117(9):2658-2667.
32. Moorman AV, Enshaei A, Schwab C, et al. A novel integrated cytogenetic and genomic classification refines risk stratification in pediatric acute lymphoblastic leukemia. Blood. 2014;124(9):1434-1444.